Phase 2 Trial Begins for Early Alzheimer’s with Sinaptica’s Neuromodulation System Sinaptica Therapeutics, Inc., a clinical-stage company focused on developing personalized neuromodulation therapies for Alzheimer’s and other neurodegenerative diseases, has announced the launch of a Phase 2 clinical trial for…
Variational AI Raises $5.5 Million to Launch Foundation Model for Drug Discovery Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, has successfully closed its oversubscribed $5.5 million Seed extension round. Enki™ is designed…
OS Therapies Granted Patent for OST-HER2 Commercial Manufacturing OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company focused on immunotherapies and targeted drug conjugates for cancer treatment, announced today that it has received a Notice of Allowance from the United…
Shape Memory Medical Begins European Enrollment in AAA-SHAPE Trial Shape Memory Medical Inc., a developer of custom shape memory polymers for endovascular markets, has announced the first European enrollment in the AAA-SHAPE Pivotal Trial. This prospective, multicenter, randomized, open-label trial…
DIA Europe 2025 to Tackle EU Reforms & Global Healthcare Harmonization DIA, a global non-profit for life sciences professionals, will host DIA Europe 2025 from March 18-20 in Basel, bringing together stakeholders to discuss healthcare system efficiencies, international collaboration, and…
Stablepharma Secures €2.5M EIC Grant, Among Top 71 EU Innovators UK biotech Stablepharma Ltd has secured a €2.5M grant from the European Innovation Council (EIC) Accelerator Programme. The funding acknowledges its innovative refrigeration-free pharmaceutical technology, meeting the EIC’s high standards…
DocGo Expands into Chattanooga Region in Collaboration with Major Tennessee Healthcare System DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced that its Ambulnz subsidiary has extended its contract with a…
Stablepharma Secures €2.5M EIC Grant, Named Top EU Innovator UK-based biotechnology firm Stablepharma Ltd has been awarded €2.5 million through the prestigious European Innovation Council (EIC) Accelerator program. The grant recognises the company’s cutting-edge fridge-free pharmaceutical technology, which meets EIC’s…
Precision BioSciences Announces Early Safety and Antiviral Results for PBGENE-HBV in ELIMINATE-B Trial Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases,…
Reverb Therapeutics Secures $12M to Advance Amplify•R™ Platform Reverb Therapeutics, a leader in harnessing the natural immune system and cytokine signaling to treat life-threatening diseases, announced it has closed a USD $12 Million financing led by founding investor Amplitude Ventures. Other…
ClearNote Health’s Avantect® Pancreatic Cancer Test Approved in New York ClearNote Health has received approval from the New York State Department of Health’s Clinical Laboratory Evaluation Program (CLEP) for its Avantect® Pancreatic Cancer Test. This approval allows New York clinicians…
Arcus Biosciences Retains Casdatifan Rights and Announces $150M Stock Offering Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage global biopharmaceutical company specializing in cancer treatments, announced today that Gilead’s exclusive option rights to its potential best-in-class HIF-2α inhibitor, casdatifan, have expired. In…